Literature DB >> 23759334

Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe.

Dewleen G Baker1, Tobias Moeller Bertram, Piyush M Patel, Donald A Barkauskas, Paul Clopton, Sejal Patel, Thomas D Geracioti, Uzair Haji, Daniel T O'Connor, Caroline M Nievergelt, Richard L Hauger.   

Abstract

Neuropeptide Y (NPY) is abundant in mammals, where it contributes to diverse behavioral and physiological functions, centrally and peripherally, but little information is available in regard to NPY cerebrospinal fluid (CSF)/plasma concentration relationships and dynamics. Since plasma NPY levels are commonly used as proxy "biomarkers" for central NPY activity in stress and mental health research in humans this study aims to better characterize the CSF/plasma NPY relationships. Subjects were eleven healthy male volunteers, admitted to the clinical research center for placement of an indwelling CSF catheter, as well as venous catheter, for 24-h collection of CSF NPY (cNPY) and plasma NPY (pNPY) samples. As observed in prior studies, group mean (SE) cNPY concentrations [792.1 (7.80) pg/mL] were higher than pNPY concentrations [220.0 (3.63) pg/mL]. For the eleven normal volunteers who had sufficient common (hourly) pNPY and cNPY data points, analysis of pNPY/cNPY concentration ratios and lagged cross-correlation analysis was completed. Average pNPY/cNPY concentration ratios ranged from .20 to .40 across study subjects, with a mean of .29. pNPY/cNPY cross correlation analyses, computed at varying time lags, were non-significant. An attempt was made to analyze the circadian rhythmicity of NPY secretion, but circadian components were not detectable. Using 24-h data collection, we characterized CSF/plasma NPY relationships, including presentation of evidence of weak CSF and plasma correlations, an important consideration for study design of NPY in stress or mental health. Published by Elsevier Ltd.

Entities:  

Keywords:  Blood brain barrier; Cerebrospinal fluid, CSF; Depression; Genetics; Neuropeptide Y, NPY; Plasma; Posttraumatic stress disorder

Mesh:

Substances:

Year:  2013        PMID: 23759334     DOI: 10.1016/j.psyneuen.2013.04.020

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  12 in total

1.  Plasma neuropeptide Y levels in Chinese patients with primary insomnia.

Authors:  Qiaoting Huang; Jiwu Liao; Yaping Liu; Huajun Liang; Ping Ma; Jiyang Pan
Journal:  Sleep Breath       Date:  2014-09-27       Impact factor: 2.816

2.  Cerebrospinal fluid neuropeptide Y in combat veterans with and without posttraumatic stress disorder.

Authors:  Renu Sah; Nosakhare N Ekhator; Lena Jefferson-Wilson; Paul S Horn; Thomas D Geracioti
Journal:  Psychoneuroendocrinology       Date:  2013-11-05       Impact factor: 4.905

Review 3.  The homeostatic role of neuropeptide Y in immune function and its impact on mood and behaviour.

Authors:  A Farzi; F Reichmann; P Holzer
Journal:  Acta Physiol (Oxf)       Date:  2015-01-09       Impact factor: 6.311

Review 4.  Hypothalamus-adipose tissue crosstalk: neuropeptide Y and the regulation of energy metabolism.

Authors:  Wei Zhang; Mark A Cline; Elizabeth R Gilbert
Journal:  Nutr Metab (Lond)       Date:  2014-06-10       Impact factor: 4.169

5.  Cerebrospinal fluid neuropeptide Y levels in major depression and reported childhood trauma.

Authors:  Laili Soleimani; Maria A Oquendo; Gregory M Sullivan; Aleksander A Mathé; J John Mann
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

6.  A Randomized Dose-Ranging Study of Neuropeptide Y in Patients with Posttraumatic Stress Disorder.

Authors:  Sehrish Sayed; Nicholas T Van Dam; Sarah R Horn; Marin M Kautz; Michael Parides; Sara Costi; Katherine A Collins; Brian Iacoviello; Dan V Iosifescu; Aleksander A Mathé; Steven M Southwick; Adriana Feder; Dennis S Charney; James W Murrough
Journal:  Int J Neuropsychopharmacol       Date:  2018-01-01       Impact factor: 5.176

Review 7.  Mechanisms of cognitive dysfunction in CKD.

Authors:  Davide Viggiano; Carsten A Wagner; Gianvito Martino; Maiken Nedergaard; Carmine Zoccali; Robert Unwin; Giovambattista Capasso
Journal:  Nat Rev Nephrol       Date:  2020-03-31       Impact factor: 28.314

Review 8.  Neuropeptide Y: A stressful review.

Authors:  Florian Reichmann; Peter Holzer
Journal:  Neuropeptides       Date:  2015-09-30       Impact factor: 3.286

9.  Anxiety Is Associated With DPPIV Alterations in Children With Selective Mutism and Social Anxiety Disorder: A Pilot Study.

Authors:  Yulia Golub; Valeska Stonawski; Anne C Plank; Anna Eichler; Oliver Kratz; Regina Waltes; Stephan von Hoersten; Veit Roessner; Christine M Freitag
Journal:  Front Psychiatry       Date:  2021-06-29       Impact factor: 4.157

10.  Composite contributions of cerebrospinal fluid GABAergic neurosteroids, neuropeptide Y and interleukin-6 to PTSD symptom severity in men with PTSD.

Authors:  Byung Kil Kim; Jennifer R Fonda; Richard L Hauger; Graziano Pinna; George M Anderson; Ivan T Valovski; Ann M Rasmusson
Journal:  Neurobiol Stress       Date:  2020-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.